SIRION Biotech Exit

SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A goal is to develop optimized cell systems for the optimized vaccine, antibody or protein production

Press releases

Sirion Logo
23. June 2021

Successful Exit for Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW – PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech

SIRION Biotech, Martinsried near Munich, will continue to grow its leading position in viral vector technologies for cell and gene therapy as part of PerkinElmerThe addition of SIRION’s offerings will complement PerkinElmer’s Horizon Discovery portfolioIn 2007 High-Tech Gründerfonds, Creathor Ventures together with KfW and Bayern Kapital were the first seed investors of SIRION Biotech GmbHThe transaction is subject to regulatory approvals Bonn, 23.06.2021 – High-Tech Gründerfonds,
9. April 2013
Viral vectors for novel cell models, gene therapy and vaccine development gain further funds from private investors
SIRION Biotech GmbH closes new financing round with additional investors SIRION Biotech GmbH has won two additional private investors, one of them being Aumenta GmbH. Both contribute to a large extent to the current financing round side by side with the existing investors Creathor Venture, HTGF, Bayernkapital and KfW, next to the Managing Directors. The new funds will further strengthen access to the Japan and USA markets and drive the evaluation of clinical programs for viral vectors and com
27. June 2011
Creathor Venture and High-Tech Gründerfonds accelerate growth of SIRION BIOTECH with further investment
Creathor Venture and current investors invest in SIRION BIOTECH and provide further funding. In addition to Creathor Venture the investors High-Tech-Gründerfonds, KfW, and Bayernkapital also joined the current round to further fund the young Munich based biotech. SIRION’s core competence lies in the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation. A part of the new proceeds will be used to further promote already developed tec

Info & Contact

Christian Thirion


Am Klopferspitz 19
82152 Planegg Martinsried

In portfolio

04. Sep 2007 – 22. Jun 2021


HTGF Manager

Marco Winzer, Partner